Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 2, 2006, Pages 852-859

  Gardiner, Sheila M ^a   March, Julie E ^a   Kemp, Philip A ^a   Bennett, Terence ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ADRENALIN; ALPHA ADRENERGIC RECEPTOR; ANGIOTENSIN RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PHENTOLAMINE; PROPRANOLOL; VASOPRESSIN RECEPTOR;

ADRENAL GLAND; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONDUCTANCE; CONSCIOUSNESS; CONTROLLED STUDY; DOSE RESPONSE; HEMODYNAMICS; INOTROPISM; MALE; MESENTERY BLOOD VESSEL; NONHUMAN; PRIORITY JOURNAL; RAT; TACHYCARDIA; VASOCONSTRICTION; VASODILATATION;

ANIMALS; AORTA, ABDOMINAL; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HEMODYNAMIC PROCESSES; HINDLIMB; MALE; MESENTERIC ARTERY, SUPERIOR; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; VASOCONSTRICTION; VASODILATION; VENOMS;

EID: 31144446219     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.093104     Document Type: Article

References (30)

1. 3 adrenoceptors. Br J Pharmacol 144:317-322.
2. Ball DI, Brittain RT, Coleman RA, Denyer LH, Jack D, Johnson M, Lunts LH, Nials AT, Sheldrick KE, and Skidmore IF (1991) Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 104:665-671.
3. Barragán JM, Eng J, Rodríguez RE, and Blázquez E (1999) Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 277:E784-E791.
4. Barragán JM, Rodríguez RE, and Blázquez E (1994) Changes in arterial blood pressure and heart rate by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 266:E459-E466.
5. Barragán JM, Rodríguez RE, Eng J, and Blázquez E (1996) Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 67:63-68.
6. Batin P, Gardiner SM, Compton AM, and Bennett T (1991) Differential regional hemodynamic effects of the non-peptide angiotensin II antagonist, DuP 753, in water-replete and water-deprived Brattleboro rats. Life Sci 48:733-739.
7. 2-selective adrenoceptor antagonist (ICI 118551). J Cardiovasc Pharmacol 5:430-437.
8. Bojanowska E and Stempniak B (2002) Effects of glucagon-like peptide-1 (7-36) amide on neurohypophysial and cardiovascular functions under hypo- or normotensive hypovolaemia in the rat. J Endocr 172:303-310.
9. Broadley KJ, Williamson KL, and Roach AG (1999) In vivo demonstration of α-adrenoceptor-mediated positive inotropy in pithed rats: evidence that noradrenaline does not stimulate myocardial α-adrenoceptors. J Auton Pharmacol 19:55-63.
10. Daniel EE, Anvari M, Fox-Threlkeld JET, and McDonald TJ (2002) Local, exendin-(9 -39)-insensitive, site of action of GLP-1 in canine ileum. Am J Physiol 283: G595-G602.
11. Drucker DJ (2001) Minireview: the glucagon-like peptides. Endocrinology 142:521-527.
12. Edwards CMB, Todd JF, Ghatei MA, and Bloom SR (1998) Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. Clin Sci 96:719-724.
13. Edwards CMB, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, and Bloom SR (1999) Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48:86-93.
14. Gardiner SM, Bennett T, and Compton AM (1988) Regional haemodynamic effects of neuropeptide Y, vasopressin and angiotensin II in conscious, unrestrained, Long-Evans and Brattleboro rats. J Auton Nerv Syst 24:15-27.
15. Gardiner SM, Compton AM, and Bennett T (1989) Regional hemodynamic changes following hypovolemia in conscious rats. Am J Physiol 256:R1076-R1083.
16. Gardiner SM, March JE, Kemp PA, and Bennett T (2002) Influence of the CB1 receptor antagonist, AM 251, on the regional haemodynamic effects of WIN-55212-2 or HU 210 in conscious rats. Br J Pharmacol 136:581-587.
17. Gardiner SM, Rakhit T, Kemp PA, March JE, and Bennett T (1994) Regional haemodynamic responses to pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide in conscious rats. Br J Pharmacol 111:589-597.
18. Golpon HA, Puechner A, Welte T, Wichert PV, and Feddersen CO (2001) Vasorelaxant effect of glucagon-like peptide-(7-36) amide and amylin on the pulmonary circulation of the rat. Regul Pept 102:81-86.
19. 2-selective agonist. J Cardiovasc Electrophysiol 15:316-322.
20. Isbil-Buyukcoskun N and Gulec G (2004) Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul Pept 118:33-38.
21. Kieffer TJ and Habener JF (1999) The glucagon-like peptides. Endocr Rev 20:876-913.
22. Knudsen LB (2004) Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J Med Chem 47:4128-4134.
23. Malendowicz LK, Nussdorfer GG, Nowak KW, Ziolkowska A, Tortorella C, and Trejter M (2003) Exendin-4, a GLP-1 receptor agonist, stimulates pituitaryadrenocortical axis in the rat: investigations into the mechanism(s) underlying Ex4 effect. Int J Mol Med 12:237-241.
24. Martin JR (2005) Peptide YY administration into the posterior hypothalamic nucleus of the rat evokes cardiovascular changes by non-adrenergic, non-cholinergic mechanisms. Auton Autacoid Pharmacol 25:53-67.
25. Nyström T, Gonon AT, Sjöholm Å, and Pernow J (2005) Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium- independent mechanism. Regul Pept 125:173-177.
26. Theodorsson-Norheim E (1987) Friedman and Quade tests: BASIC computer program to perform nonparametric two-way analysis of variance and multiple comparisons on ranks of several related samples. Comput Biol Med 17:85-99.
27. Vila Petroff MG, Egan JM, Wang X, and Sollott SJ (2001) Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 89:445-452.
28. Woolard J, Bennett T, Dunn WR, Heal DJ, Aspley S, and Gardiner SM (2004) Acute cardiovascular effects of sibutramine in conscious rats. J Pharmacol Exp Ther 308:1102-1110.
29. Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, Drucker DJ, and Elmquist JK (2003) Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic sites. J Neurosci 23:2939-2946.
30. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, et al. (2002) Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Investig 110:43-52.